

KARPAS 231 Human B-cell Leukaemia cell line

KARPAS 231 Human B-cell Leukaemia cell line useful in oncology research, developed at the University of Cambridge.

Cambridge Enterprise Limited is the exclusive licensor for the Karpas cell line portfolio. We have partnered with ECACC (The European Collection of Cell Cultures; a Public Health England Culture Collection) to manage distribution of the majority of these cells on our behalf. Enquires to either organisation are welcomed.

References

1. E Nacheva, M J Dyer, P Fischer, G Stranks, J M Heward, R E Marcus, C Grace, A Karpas(05-01-1993) , C-MYC translocations in de novo B-cell lineage acute leukemias with t(14;18)(cell lines Karpas 231 and 353), <https://www.sciencedirect.com/science/article/pii/S0006497120813378?via%3Dihub>, 82, 231-240
2. S Galiègue Zouitina, S Quief, M P Hildebrand, C Denis, G Lecocq, M Collyn-d'Hooghe, C Bastard, M Yuille, M J Dyer, J P Kerckaert(10-04-1996) , <https://pubmed.ncbi.nlm.nih.gov/8618432/>, 4, 579-587
3. T G Willis, D M Jadayel, L J Coignet, M Abdul-Rauf, J G Treleaven, D Catovsky, M J Dyer(15-09-1997) , <https://pubmed.ncbi.nlm.nih.gov/9310498/>, <https://pubmed.ncbi.nlm.nih.gov/9310498/>, 90, 2456-2464

Category

Monoclonal Hybridomas
Cell Lines

Learn more

